Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Malnutrition | 4 | 2020 | 28 | 1.610 |
Why?
|
| Diabetic Foot | 1 | 2021 | 33 | 0.780 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2020 | 207 | 0.770 |
Why?
|
| Nutritional Status | 3 | 2020 | 112 | 0.750 |
Why?
|
| Dietary Supplements | 3 | 2020 | 332 | 0.750 |
Why?
|
| Carrier State | 2 | 2011 | 39 | 0.730 |
Why?
|
| Nasal Cavity | 2 | 2011 | 62 | 0.720 |
Why?
|
| Pneumonia | 2 | 2020 | 110 | 0.710 |
Why?
|
| Hand Strength | 1 | 2020 | 47 | 0.700 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2011 | 92 | 0.700 |
Why?
|
| Hyperandrogenism | 1 | 2019 | 2 | 0.690 |
Why?
|
| Hyperprolactinemia | 1 | 2019 | 3 | 0.690 |
Why?
|
| Cushing Syndrome | 1 | 2019 | 7 | 0.690 |
Why?
|
| Hirsutism | 1 | 2019 | 6 | 0.690 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2019 | 13 | 0.680 |
Why?
|
| Adrenal Hyperplasia, Congenital | 1 | 2019 | 23 | 0.680 |
Why?
|
| Staphylococcal Infections | 2 | 2011 | 156 | 0.670 |
Why?
|
| Biomarkers | 4 | 2017 | 1593 | 0.660 |
Why?
|
| Thyroid Diseases | 1 | 2019 | 33 | 0.660 |
Why?
|
| Anti-Bacterial Agents | 2 | 2021 | 1026 | 0.540 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2017 | 91 | 0.530 |
Why?
|
| Myocardial Infarction | 2 | 2020 | 807 | 0.520 |
Why?
|
| Simulation Training | 1 | 2015 | 49 | 0.470 |
Why?
|
| Nutrition Surveys | 8 | 2013 | 208 | 0.450 |
Why?
|
| Cholesterol | 2 | 2017 | 331 | 0.440 |
Why?
|
| Headache | 1 | 2013 | 68 | 0.430 |
Why?
|
| Life Style | 2 | 2012 | 338 | 0.430 |
Why?
|
| Heart Failure | 2 | 2020 | 1180 | 0.410 |
Why?
|
| Coffee | 1 | 2011 | 18 | 0.390 |
Why?
|
| Tea | 1 | 2011 | 23 | 0.390 |
Why?
|
| Aging | 1 | 2017 | 911 | 0.380 |
Why?
|
| Risk Factors | 9 | 2021 | 5731 | 0.370 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 174 | 0.360 |
Why?
|
| Overweight | 1 | 2012 | 186 | 0.360 |
Why?
|
| Aged | 15 | 2020 | 14862 | 0.350 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2009 | 12 | 0.350 |
Why?
|
| Pesticides | 1 | 2010 | 41 | 0.350 |
Why?
|
| Shellfish | 1 | 2009 | 8 | 0.340 |
Why?
|
| Perimenopause | 1 | 2009 | 3 | 0.340 |
Why?
|
| Onions | 1 | 2009 | 4 | 0.340 |
Why?
|
| Cholesterol, Dietary | 1 | 2009 | 22 | 0.340 |
Why?
|
| Body Mass Index | 5 | 2017 | 867 | 0.340 |
Why?
|
| Feeding Behavior | 1 | 2011 | 224 | 0.340 |
Why?
|
| Hypersensitivity | 1 | 2009 | 52 | 0.340 |
Why?
|
| Internship and Residency | 1 | 2015 | 596 | 0.330 |
Why?
|
| Postmenopause | 1 | 2009 | 93 | 0.330 |
Why?
|
| Humans | 26 | 2021 | 68618 | 0.320 |
Why?
|
| Dietary Proteins | 2 | 2020 | 51 | 0.310 |
Why?
|
| Bone Density | 1 | 2009 | 159 | 0.310 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2008 | 22 | 0.310 |
Why?
|
| Neoplasms | 1 | 2019 | 1667 | 0.310 |
Why?
|
| Environmental Exposure | 1 | 2010 | 269 | 0.300 |
Why?
|
| Vitamin D Deficiency | 1 | 2010 | 292 | 0.290 |
Why?
|
| Coronary Disease | 1 | 2009 | 358 | 0.290 |
Why?
|
| Female | 19 | 2020 | 38074 | 0.290 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2008 | 147 | 0.280 |
Why?
|
| Diet | 2 | 2011 | 514 | 0.280 |
Why?
|
| Middle Aged | 14 | 2017 | 21147 | 0.270 |
Why?
|
| Stroke | 2 | 2009 | 2163 | 0.270 |
Why?
|
| Valerates | 3 | 2020 | 3 | 0.270 |
Why?
|
| Male | 18 | 2020 | 37321 | 0.260 |
Why?
|
| Obesity | 1 | 2012 | 1076 | 0.240 |
Why?
|
| Hospitalization | 4 | 2020 | 978 | 0.240 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 694 | 0.230 |
Why?
|
| Uric Acid | 2 | 2014 | 37 | 0.220 |
Why?
|
| United States | 10 | 2013 | 7367 | 0.220 |
Why?
|
| Shoes | 1 | 2021 | 8 | 0.200 |
Why?
|
| Double-Blind Method | 3 | 2020 | 1738 | 0.200 |
Why?
|
| Debridement | 1 | 2021 | 55 | 0.200 |
Why?
|
| Bandages | 1 | 2021 | 33 | 0.200 |
Why?
|
| Logistic Models | 5 | 2011 | 1420 | 0.190 |
Why?
|
| Activities of Daily Living | 2 | 2020 | 319 | 0.190 |
Why?
|
| Nutritional Support | 1 | 2020 | 22 | 0.180 |
Why?
|
| Cohort Studies | 4 | 2011 | 2358 | 0.180 |
Why?
|
| Glucocorticoids | 2 | 2019 | 222 | 0.180 |
Why?
|
| C-Reactive Protein | 2 | 2011 | 180 | 0.170 |
Why?
|
| Hypertension | 2 | 2010 | 1535 | 0.170 |
Why?
|
| Energy Intake | 1 | 2020 | 123 | 0.170 |
Why?
|
| Hair Removal | 1 | 2019 | 2 | 0.170 |
Why?
|
| Ornithine Decarboxylase Inhibitors | 1 | 2019 | 7 | 0.170 |
Why?
|
| Odds Ratio | 3 | 2011 | 880 | 0.170 |
Why?
|
| Leuprolide | 1 | 2019 | 6 | 0.170 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2019 | 8 | 0.170 |
Why?
|
| Spironolactone | 1 | 2019 | 13 | 0.170 |
Why?
|
| Eflornithine | 1 | 2019 | 15 | 0.170 |
Why?
|
| Aftercare | 1 | 2020 | 114 | 0.170 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2019 | 25 | 0.170 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2019 | 32 | 0.170 |
Why?
|
| Androgen Antagonists | 1 | 2019 | 45 | 0.170 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2019 | 99 | 0.160 |
Why?
|
| Adult | 9 | 2013 | 21403 | 0.160 |
Why?
|
| Patient Discharge | 1 | 2020 | 294 | 0.150 |
Why?
|
| Proportional Hazards Models | 2 | 2012 | 792 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 148 | 0.150 |
Why?
|
| Serum Albumin, Human | 1 | 2017 | 10 | 0.150 |
Why?
|
| Doxepin | 1 | 2017 | 5 | 0.150 |
Why?
|
| Nutrition Assessment | 1 | 2017 | 43 | 0.150 |
Why?
|
| Prealbumin | 1 | 2017 | 25 | 0.150 |
Why?
|
| Melatonin | 1 | 2017 | 39 | 0.150 |
Why?
|
| Hemoglobins | 1 | 2017 | 120 | 0.140 |
Why?
|
| Hypnotics and Sedatives | 1 | 2017 | 96 | 0.140 |
Why?
|
| Benzodiazepines | 1 | 2017 | 130 | 0.140 |
Why?
|
| Protein-Energy Malnutrition | 1 | 2016 | 4 | 0.140 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 1851 | 0.130 |
Why?
|
| Morbidity | 1 | 2016 | 130 | 0.130 |
Why?
|
| Linear Models | 1 | 2017 | 521 | 0.130 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 4848 | 0.130 |
Why?
|
| Vitamin D | 2 | 2010 | 516 | 0.130 |
Why?
|
| Acute Disease | 2 | 2016 | 658 | 0.130 |
Why?
|
| Gout | 1 | 2014 | 9 | 0.120 |
Why?
|
| Young Adult | 5 | 2012 | 5717 | 0.120 |
Why?
|
| Blood Pressure | 2 | 2011 | 1451 | 0.110 |
Why?
|
| Child, Preschool | 2 | 2011 | 3187 | 0.110 |
Why?
|
| Cluster Headache | 1 | 2013 | 3 | 0.110 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 1465 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1140 | 0.110 |
Why?
|
| Population Growth | 1 | 2013 | 6 | 0.110 |
Why?
|
| Patient Readmission | 1 | 2016 | 267 | 0.110 |
Why?
|
| Population Dynamics | 1 | 2013 | 30 | 0.110 |
Why?
|
| Life Expectancy | 1 | 2013 | 51 | 0.110 |
Why?
|
| Medical History Taking | 1 | 2013 | 94 | 0.110 |
Why?
|
| Health Surveys | 2 | 2012 | 489 | 0.110 |
Why?
|
| Age Factors | 1 | 2017 | 1864 | 0.100 |
Why?
|
| Physical Examination | 1 | 2013 | 152 | 0.100 |
Why?
|
| Migraine Disorders | 1 | 2013 | 66 | 0.100 |
Why?
|
| Family Practice | 1 | 2015 | 312 | 0.100 |
Why?
|
| Chi-Square Distribution | 2 | 2010 | 546 | 0.100 |
Why?
|
| Iron Overload | 1 | 2011 | 28 | 0.100 |
Why?
|
| Cholesterol, LDL | 1 | 2011 | 161 | 0.090 |
Why?
|
| Mortality | 1 | 2012 | 163 | 0.090 |
Why?
|
| Hot Temperature | 1 | 2011 | 152 | 0.090 |
Why?
|
| Medicare Part D | 1 | 2010 | 5 | 0.090 |
Why?
|
| Food Labeling | 1 | 2010 | 10 | 0.090 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2011 | 98 | 0.090 |
Why?
|
| Patients | 1 | 2010 | 69 | 0.090 |
Why?
|
| Skin Tests | 1 | 2009 | 30 | 0.090 |
Why?
|
| Drug Costs | 1 | 2010 | 87 | 0.090 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 2010 | 38 | 0.090 |
Why?
|
| Child | 2 | 2011 | 6405 | 0.090 |
Why?
|
| Bacterial Infections | 1 | 2011 | 163 | 0.090 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2009 | 20 | 0.080 |
Why?
|
| Health Status Disparities | 1 | 2013 | 326 | 0.080 |
Why?
|
| Calcium, Dietary | 1 | 2009 | 35 | 0.080 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2009 | 38 | 0.080 |
Why?
|
| Absorptiometry, Photon | 1 | 2009 | 83 | 0.080 |
Why?
|
| Hip Fractures | 1 | 2009 | 26 | 0.080 |
Why?
|
| Confidence Intervals | 1 | 2009 | 242 | 0.080 |
Why?
|
| Drug Prescriptions | 1 | 2010 | 135 | 0.080 |
Why?
|
| Parathyroid Hormone | 1 | 2009 | 117 | 0.080 |
Why?
|
| Cost of Illness | 1 | 2010 | 206 | 0.080 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2008 | 59 | 0.080 |
Why?
|
| South Carolina | 1 | 2015 | 2752 | 0.080 |
Why?
|
| Causality | 1 | 2008 | 82 | 0.080 |
Why?
|
| Adolescent | 2 | 2011 | 8912 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2009 | 714 | 0.080 |
Why?
|
| Environmental Pollutants | 1 | 2010 | 180 | 0.080 |
Why?
|
| Lipids | 1 | 2009 | 298 | 0.070 |
Why?
|
| ROC Curve | 1 | 2008 | 392 | 0.070 |
Why?
|
| Exercise | 2 | 2011 | 658 | 0.070 |
Why?
|
| Cardiovascular Diseases | 2 | 2011 | 940 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2010 | 1330 | 0.060 |
Why?
|
| Incidence | 1 | 2009 | 1603 | 0.060 |
Why?
|
| Smoking | 2 | 2011 | 1452 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2011 | 3705 | 0.060 |
Why?
|
| Asthma | 1 | 2008 | 345 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 1753 | 0.060 |
Why?
|
| Comorbidity | 1 | 2008 | 1426 | 0.060 |
Why?
|
| Infant | 1 | 2010 | 2891 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2009 | 3259 | 0.050 |
Why?
|
| Cross-Sectional Studies | 3 | 2011 | 2279 | 0.040 |
Why?
|
| Length of Stay | 2 | 2016 | 780 | 0.040 |
Why?
|
| Placebos | 1 | 2020 | 195 | 0.040 |
Why?
|
| Nutrition Therapy | 1 | 2016 | 21 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2016 | 82 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 2093 | 0.030 |
Why?
|
| Gout Suppressants | 1 | 2014 | 7 | 0.030 |
Why?
|
| Patient Acuity | 1 | 2014 | 17 | 0.030 |
Why?
|
| Diet Therapy | 1 | 2014 | 22 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 411 | 0.030 |
Why?
|
| Body Weight | 1 | 2016 | 554 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2014 | 291 | 0.030 |
Why?
|
| Disease Management | 1 | 2014 | 248 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 240 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2013 | 117 | 0.030 |
Why?
|
| Animals | 1 | 2009 | 20881 | 0.030 |
Why?
|
| Ferritins | 1 | 2011 | 49 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2011 | 114 | 0.020 |
Why?
|
| Proteinuria | 1 | 2011 | 136 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2011 | 114 | 0.020 |
Why?
|
| Age Distribution | 1 | 2011 | 320 | 0.020 |
Why?
|
| Serum | 1 | 2010 | 24 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2010 | 90 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2010 | 99 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 425 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1054 | 0.020 |
Why?
|
| Prevalence | 1 | 2011 | 1619 | 0.020 |
Why?
|
| Health Behavior | 1 | 2010 | 458 | 0.020 |
Why?
|
| Liver | 1 | 2011 | 1118 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2011 | 805 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 2007 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 767 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2016 | 7029 | 0.010 |
Why?
|
| Inflammation | 1 | 2010 | 1030 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2010 | 1085 | 0.010 |
Why?
|